BSE List Price : ₹59.75

subscription

Category	Times
QIBs	180.22x
HNIs	1662.39x
Retail	881.15x
Total : 840.81x

IPO Market Lot(s) Distribution

Application	Lot Size	Shares	Amount
Retail Minimum	2	6,000	₹258,000
Retail Maximum	2	6,000	₹258,000
S-HNI Minimum	3	9,000	₹387,000
S-HNI Maximum	7	21,000	₹903,000
B-HNI Minimum	8	24,000	₹1,032,000

About the Company

Goldline Pharmaceuticals
 is a prominent pharmaceutical company engaged in the marketing and distribution of a wide range of healthcare products under the brand name Goldline. The company operates through five major divisions:

1.Goldline Pharma – catering to specialties such as Physicians, Orthopedics, ENT, Chest Physicians, General and Specialized Surgery, Gastroenterology, Neurology, and Urology.
2.Goldline Cardinal – focused on areas including Physicians, Diabetology, Endocrinology, Cardiology, and General Medicine.
3.Goldline Ayushman – serving Pediatricians, Child Care Specialists, Neonatologists, and General Practitioners.
4.Goldline InLife – dedicated to Intensivists, Critical Care Specialists, Super Specialty Surgeons, and Physicians.
5.Goldline Wellness – specializing in oncology and cancer-related therapies.

The company markets and distributes its products across several Indian states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. All products are promoted and sold under the unified Goldline brand.

Company Financial Report

_{Amount ₹ in Crores}

Period Ended	Revenue	Expense	PAT	Assets
2023	₹19.85	₹19.45	₹0.26	₹19.39
2024	₹23.57	₹21.04	₹1.81	₹22.93
2025	₹28.06	₹24.20	₹2.83	₹26.28

Company Promoter

Amol Laxmikant Mujumdar

Swapan Premprakash Khandelwal

Know before investing

• • Strengths

  Experienced promoters and a skilled management team: The company benefits from leadership with extensive experience in the pharmaceutical sector, enabling effective product placement, business growth, and strong relationships with distributors.

  Broad therapeutic product range: The company’s presence in various medical specialties helps minimize reliance on any one therapeutic segment while enhancing its reach across diverse markets.

• • Risks

  Reliance on outsourced manufacturing: The company is fully dependent on third-party manufacturers, and any disruptions related to quality standards, regulatory compliance, or supply chain issues could negatively impact its operations and reputation.

  Risk related to market evaluation and product selection: The company’s growth is dependent on choosing pharmaceutical products with strong market potential, and any inability to correctly gauge market demand could adversely affect its revenue and profitability.

Objects of the Issue & Utilisation of proceeds

Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company.

General Corporate Purpose.

Company  Address

Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/

IPO Registrar

Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html

IPO Review

May Apply